Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Merck Sharp & Dohme Corp. patent solves the following problem:

Spleen Tyrosine Kinase (SYK) is a protein tyrosine kinase described as a key mediator of immunoreceptor signaling a host of inflammatory cells including mast cells, B-cells, macrophages and neutrophils. These immunoreceptors, including Fc receptor and the B-cell receptor, is important for allergic diseases, and antibody-mediated autoimmune diseases and thus pharmacologically interfering SYK conceivably treat these diseases.

Our analysis of this patent is as follows:

Merck Sharp & Dohme Corp.’s patent US 9416111 B2 deals with Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors.
invention provides certain substituted diazine and triazine compounds of Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, P3, R4, rcy, CY, and t as described here. invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated spleen tyrosine kinase (SYK) kinase.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Merck Sharp & Dohme Corp., , Merck Canada Inc. patent solves the following problem:

Spleen Tyrosine Kinase (SYK) is a protein tyrosine kinase described as a key mediator of immunoreceptor signaling a host of inflammatory cells including mast cells, B-cells, macrophages and neutrophils. These immunoreceptors, including Fc receptor and the B-cell receptor, is important for allergic diseases, and antibody-mediated autoimmune diseases and thus pharmacologically interfering SYK conceivably treat these diseases.

Our analysis of this patent is as follows:

Merck Sharp & Dohme Corp., , Merck Canada Inc.’s patent US 9353066 B2 deals with Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors.
invention provides certain substituted phenyl compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, P3, R4, RCY, and t as described here. invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated spleen tyrosine kinase (SYK).

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Merck Sharp & Dohme Corp. patent solves the following problem:

Spleen Tyrosine Kinase (SYK) is a protein tyrosine kinase described as a key mediator of immunoreceptor signaling a host of inflammatory cells including mast cells, B-cells, macrophages and neutrophils. These immunoreceptors, including Fc receptor and the B-cell receptor, is important for allergic diseases, and antibody-mediated autoimmune diseases and thus pharmacologically interfering SYK conceivably treat these diseases.

Our analysis of this patent is as follows:

Merck Sharp & Dohme Corp.’s patent US 9216173 B2 deals with 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors.
invention provides certain 2-pyridyl formamide-containing compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein A and B as described here. invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated spleen tyrosine kinase (SYK) kinase.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Uronic acid and probiotics of Lactobacillus paracasei and Bifidobacterium breve for in vivo treatment of infection

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The N.V. Nutricia patent solves the following problem:

Infant formula generally aim to capture the compositional features and (protective) effects of human breast milk. A major step forward in the development of this is the inclusion of prebiotic fiber in the formula. Prebiotic fiber is also present in human breast milk and stimulates a healthy development of the intestinal flora. It also recently found that oral ingestion of prebiotic fibers stimulates the development of a healthy immune system. A more recent development is the inclusion of probiotic bacteria in baby formula. Many studies suggest beneficial effects of the oral administration of probiotic bacteria.

Our analysis of this patent is as follows:

N.V. Nutricia’s patent US 9168267 B2 deals with Uronic acid and probiotics of Lactobacillus paracasei and Bifidobacterium breve for in vivo treatment of infection.
The present invention relates to compositions containing probiotic bacteria and uronic acid oligosaccharides. The composition may be used as child nutrition and beneficial way to reduce the incidence of infection.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Preventing diseases in infants delivered via caesarean section

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The N.V. Nutricia patent solves the following problem:

Human milk contains non-digestible oligosaccharides which specifically stimulate the growth of lactic acid bacteria, such as species belonging to the genus Bifidobacterium and Lactobacillus and prevent the growth and / or adhesion to the intestinal wall of other ( pathogenic) bacteria. Therefore, when a child receives human milk, intestinal flora in infants into a healthy plant rich in lactic acid bacteria. The presence of a healthy intestinal flora improves gut barrier maturation and / or gut barrier integrity, stimulates the formation of mucus, inhibits pathogenic bacteria and stimulates the immune system.

Our analysis of this patent is as follows:

N.V. Nutricia’s patent US 9107438 B2 deals with Preventing diseases in infants delivered via caesarean section.
The present invention provides the use of a composition comprising non-digestible oligosaccharide for the manufacture of a composition for enteral administration of a baby delivered by caesarean section.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Cross-environment event notification

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Z124 patent solves the following problem:

This relates generally to the field of mobile environments Computing, and especially to support many user environment through the use of multiple operating systems on a single mobile computing device.

Our analysis of this patent is as follows:

Z124’s patent US 9071625 B2 deals with Cross-environment event notification.
A mobile computing devices with a mobile operating systems and desktop operating systems running simultaneously and independently on a shared grain without virtualization. The mobile operating system provides a user experience for mobile computing devices that case the mobile environment. The desktop operating system provides a complete desktop user experience when the mobile computing device is docked to a second user environment. Cross-around title and event handling allow the user to be informed and to respond to events that occurred in the mobile operating system by about user associated with the desktop operating system. Events that may trigger cross-around title will be local events and / or isolated events. The mobile computing device may be a smartphone running the Android mobile operating system and a complete desktop Linux distribution on a modified Android kernel.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Application mirroring using multiple graphics contexts

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Z124 patent solves the following problem:

This relates generally to the field of mobile environments Computing, and especially to support many user environment through the use of multiple operating systems on a single mobile computing device.

Our analysis of this patent is as follows:

Z124’s patent US 9060006 B2 deals with Application mirroring using multiple graphics contexts.
Cross-around providing support and companionship user to provide a seamless computing experience in a multi-operating system environment Computing. Cross-around naked provides real-time display of the application running on a mobile operating system that is shown in an environment of a desktop operating system. The mobile operating systems and desktop operating system will be running simultaneously and independently on a shared grain on a mobile device Computing. A graphic server mobile operating system in tears and rebuilds the rendering context for each application as it mixed information face. The rendering context can be strengthened to match the resolution of the associated display, so the graphics are rendered appropriate for resolution. The mobile computing device may be a smartphone running the Android mobile operating system and a complete desktop Linux distribution on a modified Android kernel.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Truck fairing

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Volvo Group North America, Llc patent solves the following problem:

From increasing fuel costs continue to encourage strict and semi-trailer tractors designers to search for additional, novel ways to improve vehicle fuel economy. Negative effects of airflow during the trip is always a place to focus, and manufacturers reduce aerodynamic drag, for example, again out forms to avoid the restraint force working directly any moving body Airstream encounter. Fairings, things, foil, covered with hoods, rolled under the bumpers, recessed door handles add to the cost of design and weight, and complicate car repair and servicing. Nevertheless, the designers' goal was to offset these negative effects to a general decrease in drag coefficient as car fuel economy may increase.

Our analysis of this patent is as follows:

Volvo Group North America, Llc’s patent US 9027686 B2 deals with Truck fairing.
A truck includes a frame, an operator cab frame, and a drive axle with a differential. differential can be connected to a drive shaft. A fairing for directing the air flow around the differential is attached to the frame before the drive axle and the front differential. fairing may have a non-deflected position and a deflected position.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Merck Sharp & Dohme Corp. patent solves the following problem:

Spleen Tyrosine Kinase (SYK) is a protein tyrosine kinase described as a key mediator of immunoreceptor signaling a host of inflammatory cells including mast cells, B-cells, macrophages and neutrophils. These immunoreceptors, including Fc receptor and the B-cell receptor, is important for allergic diseases, and antibody-mediated autoimmune diseases and thus pharmacologically interfering SYK conceivably treat these diseases.

Our analysis of this patent is as follows:

Merck Sharp & Dohme Corp.’s patent US 8987456 B2 deals with 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors.
invention provides certain 3-pyridyl formamide-containing compounds of Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein A and B as described here. invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated spleen tyrosine kinase (SYK) kinase.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Milk-based nutritional compositions containing lactoferrin and uses thereof

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Mead Johnson Nutrition Company patent solves the following problem:

Lactoferrin, an iron-binding glycoprotein, is one of the major multifunctional house agents in human milk. It has the capacity to bind to two molecules of iron in a consistent manner and facilitate the uptake of iron in the intestine. Moreover, lactoferrin has been shown that both bacteriostatic and bactericidal, and it helps to prevent intestinal infections in humans, especially in pediatric subjects.

Our analysis of this patent is as follows:

Mead Johnson Nutrition Company’s patent US 8968722 B2 deals with Milk-based nutritional compositions containing lactoferrin and uses thereof.
The present disclosure relates to milk-based nutritional composition comprising lactoferrin and / or a prebiotic component, which, when combined, lactoferrin and prebiotic component to show additive or synergistic beneficial effects on the health and development of a pediatric subjects. disclosure further relates to methods comprising the administration of the milk-based nutritional composition in pediatric subjects.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.